Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying.
Hellström PM, Tack J, Johnson LV, Hacquoil K, Barton ME, Richards DB, Alpers DH, Sanger GJ, Dukes GE. Hellström PM, et al. Among authors: hacquoil k. Br J Pharmacol. 2016 Jun;173(11):1768-77. doi: 10.1111/bph.13475. Epub 2016 Apr 13. Br J Pharmacol. 2016. PMID: 26924243 Free PMC article. Clinical Trial.
First-in-Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
Cooper M, O'Connor-Semmes R, Reedy BA, Hacquoil K, Gorycki P, Pannullo K, Verticelli A, Shakib S. Cooper M, et al. Among authors: hacquoil k. Clin Pharmacol Drug Dev. 2019 Feb;8(2):234-245. doi: 10.1002/cpdd.600. Epub 2018 Sep 13. Clin Pharmacol Drug Dev. 2019. PMID: 30277655 Clinical Trial.
First-in-Human Study for a Selective Rearranged During Transfection Tyrosine Kinase Inhibitor, GSK3352589, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
Reedy BA, O'Connor-Semmes R, Hacquoil K, Gorycki P, Verticelli A, Molga A. Reedy BA, et al. Among authors: hacquoil k. Clin Pharmacol Drug Dev. 2021 Apr;10(4):334-345. doi: 10.1002/cpdd.911. Epub 2021 Feb 19. Clin Pharmacol Drug Dev. 2021. PMID: 33606922 Clinical Trial.
Pharmacokinetics and safety of inhaled oxytocin compared with intramuscular oxytocin in women in the third stage of labour: A randomized open-label study.
Gajewska-Knapik K, Kumar S, Sutton-Cole A, Palmer KR, Cahn A, Gibson RA, Kirkpatrick C, Parry S, Schneider I, Siederer S, Stylianou A, Hacquoil K, Powell M, Ellis M, McIntosh MP, Lambert P. Gajewska-Knapik K, et al. Among authors: hacquoil k. Br J Clin Pharmacol. 2023 Dec;89(12):3681-3689. doi: 10.1111/bcp.15860. Epub 2023 Aug 31. Br J Clin Pharmacol. 2023. PMID: 37485589 Clinical Trial.
Nutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE Study.
Deane AM, Lamontagne F, Dukes GE, Neil D, Vasist L, Barton ME, Hacquoil K, Ou X, Richards D, Stelfox HT, Mehta S, Day AG, Chapman MJ, Heyland DK. Deane AM, et al. Among authors: hacquoil k. JPEN J Parenter Enteral Nutr. 2018 Jul;42(5):949-959. doi: 10.1002/jpen.1038. Epub 2017 Dec 28. JPEN J Parenter Enteral Nutr. 2018. PMID: 29957868 Clinical Trial.
The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial.
Chapman MJ, Deane AM, O'Connor SL, Nguyen NQ, Fraser RJ, Richards DB, Hacquoil KE, Vasist Johnson LS, Barton ME, Dukes GE. Chapman MJ, et al. Among authors: hacquoil ke. Crit Care. 2016 Aug 1;20(1):232. doi: 10.1186/s13054-016-1420-4. Crit Care. 2016. PMID: 27476581 Free PMC article. Clinical Trial.